[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Ruxolitinib 5 mg + standard of care\t\t\t\tType of group;1 N\u00b0 of participants:40 Intervention(s) description:One ruxolitinib 5 mg tablet will be administered orally twice per day approximately 12 hours apart in addition to the standar of care treatment for 14 days. Additional 14 days of study drug may be given in the opinion of the investigator. If a patient becomes intubated during the course of the study; study drug can be administered through a nasogastric tube.\t\t\t\tGroup name:Placebo + standard of care\t\t\t\tType of group;1 N\u00b0 of participants:20 Intervention(s) description:One ruxolitinib matching placebo tablet will be administered orally twice per day approximately 12 hours apart in addition to the standar of care treatment for 14 days. Additional 14 days of study drug may be given in the opinion of the investigator.. If a patient becomes intubated during the course of the study; placebo treatment can be administered through a nasogastric tube.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1135, "treatment_name": "Ruxolitinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:Ruxolitinib 5 mg + standard of care Type of group;1 N\u00b0 of participants:40 Intervention(s) description:One ruxolitinib 5 mg tablet will be administered orally twice per day approximately 12 hours apart in addition to the standar of care treatment for 14 days. Additional 14 days of study drug may be given in the opinion of the investigator. If a patient becomes intubated during the course of the study; study drug can be administered through a nasogastric tube.\tGroup name:Placebo + standard of care Type of group;1 N\u00b0 of participants:20 Intervention(s) description:One ruxolitinib matching placebo tablet will be administered orally twice per day approximately 12 hours apart in addition to the standar of care treatment for 14 days. Additional 14 days of study drug may be given in the opinion of the investigator.. If a patient becomes intubated during the course of the study; placebo treatment can be administered through a nasogastric tube.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]